fulgentgenetics.com - FLGT Enterprise Value-to-Sales Ratio

Official company branding of Fulgent Genetics Inc (FLGT)

The enterprise value-to-revenue multiple demonstrates the dependence of Fulgent Genetics, Inc. (FLGT) on insurance reimbursement and oncology screening volumes, with the current level standing at 1223.79. The business relies on a high-performance staff of bioinformaticians and a modern DNA analysis IT platform. Currently, the revenue structure is balanced by subscription-based clinical genetics and pharmacological services, which has successfully neutralized the impact of pandemic testing.

fulgentgenetics.com (FLGT): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Fulgent Corp (FLGT)

Fundamental company valuation:FLGT Fulgent Genetics, Inc.
Manufactured products of Fulgent Genetics Inc

To objectively evaluate an issuer, a manager requires a tool that eliminates the impact of debt load on valuation. This indicator compares the total enterprise value to annual revenue, revealing actual market overvaluation or undervaluation. By analyzing the EV/Revenue ratio, an investor determines the strength of the pricing momentum regardless of financial obligations. For Fulgent Genetics, Inc. (FLGT), such transparency is critical. The humanitarian status of genetic research minimizes geopolitical risks, stabilizing the fundamental value of the company.

Competitor analysis for Fulgent Genetics, Inc.

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|LAB (Standard BioTools Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Cytek Biosciences Inc|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue